Skip to content

Database / MariTide

In Phase 3GLP-1 agonist + GIP receptor blocker (antibody)Injection · Monthly

MariTide

Maridebart cafraglutide · Amgen. A once-a-month injection that blocks GIP rather than activating it. Weight loss had not plateaued at one year.

Average weight loss
20%
Stopped for side effects
11%
Trial length
52 wk
Ranking score
n/r

Phase 2 results

Phase 2 · 52 weeks · Up to 420 mg monthly
Adults with obesity, no diabetes (n=465)

Weight loss
20.0%
Nausea
n/r
Vomiting
n/r
Diarrhea
n/r
Constipation
n/r
Quit due to side effects
11.0%

n/r = not reported.

Worth knowing

  • Phase 3 MARITIME program reads out from 2027.
  • About 11% stopped for side effects in the dose-escalation arm.

Next catalysts

2027 First MariTide Phase 3 (MARITIME) readouts (Trial estimate)

–
Not yet ranked
Needs Phase 3 data. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company
Amgen
Targets
GLP-1, GIP (blocked)
Molecule
Antibody-peptide conjugate
Dosing
Injection, monthly
Status
In Phase 3

Compare with another drug

Sources